$Sonnet BioTherapeutic (SONN.US)$ NEWS Sonnet BioTherapeutic...
NEWS
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
Sonnet BioTherapeutics (NASDAQ:SONN) has announced updated clinical data for its drug candidate SON-1010, used as a monotherapy or in combination with atezolizumab (Tecentriq®). The trials have enrolled a total of 61 subjects with dose escalation continuing in SB101 and SB221 trials. SON-1010 showed no dose-limiting toxicities and revealed a 10-fold extended half-life compared to rhIL-12, prolonging IFNγ responses without cytokine release syndrome. Clinical benefits were observed in 35% of evaluable patients with advanced solid tumors. Both trials reported stable disease in 60% of patients at the first follow-up scan. Sonnet is increasing the target dose of SON-1010 to enhance efficacy. SON-1010 was also tested in a Phase 1 trial (SB102) in healthy volunteers, showing a consistent safety profile. Sonnet’s Chief Medical Officer, Dr. Richard Kenney, emphasized the clean data generated for pharmacokinetic and pharmacodynamic analyses. The combination of SON-1010 with atezolizumab may benefit from turning 'cold' tumors 'hot,' upregulating PD-L1. The company plans to further test the drug in higher doses later this year and expects more updates early next year.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment